What is Lyell?
Operating as Lyell, the company is at the forefront of developing next-generation chimeric antigen receptor T-cell therapies. By focusing on the fundamental challenges of cell exhaustion and durability, Lyell aims to transform the standard of care for patients suffering from hematologic malignancies and solid tumors. The firm's research and development pipeline is engineered to enhance the potency and persistence of immune cells, positioning the company as a critical player in the evolving landscape of precision medicine and cellular immunotherapy. Through its rigorous scientific methodology, Lyell seeks to provide durable clinical benefits where traditional therapeutic modalities have historically struggled to achieve long-term remission.
How much funding has Lyell raised?
Lyell has raised a total of $100M across 1 funding round:
Stock/Share Issuance
$100M
Stock/Share Issuance (2025): $100M, investors not publicly disclosed
Key Investors in Lyell
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Lyell?
The recent influx of capital is expected to accelerate the company's clinical development programs and expand its manufacturing capabilities. As Lyell transitions through its current lifecycle stage, the focus will likely shift toward scaling its proprietary technology platforms and advancing its lead candidates through critical regulatory milestones. By leveraging this major enterprise-level funding, the organization is well-positioned to navigate the complexities of late-stage clinical trials, ultimately aiming to bring transformative, long-lasting treatment options to a broader patient population facing difficult-to-treat cancers.
See full Lyell company page
